

Sung-Youl Ko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4791425/publications.pdf>

Version: 2024-02-01

30
papers

3,559
citations

279798

23
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

5393
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	10.3	50
2	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	30
3	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV</i> , 2019, 6, e667-e679.	4.7	67
4	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	42
5	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	4.7	20
6	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	3.4	62
7	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	12.6	348
8	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , 2015, 24, 1019-1030.	7.6	11
9	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	3.4	92
10	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. <i>Vaccine</i> , 2015, 33, 7344-7351.	3.8	16
11	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 8334-8345.	3.4	100
12	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	12.4	222
13	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	3.4	248
14	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014, 514, 642-645.	27.8	308
15	Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>Science</i> , 2013, 342, 592-598.	12.6	797
16	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. <i>Journal of Virology</i> , 2012, 86, 7760-7770.	3.4	31
17	Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination. <i>Journal of Virology</i> , 2009, 83, 2201-2215.	3.4	61
18	Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. <i>Journal of Virology</i> , 2009, 83, 7166-7175.	3.4	23

#	ARTICLE	IF	CITATIONS
19	Enhanced Induction of Intestinal Cellular Immunity by Oral Priming with Enteric Adenovirus 41 Vectors. <i>Journal of Virology</i> , 2009, 83, 748-756.	3.4	25
20	Sublingual vaccination with influenza virus protects mice against lethal viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1644-1649.	7.1	186
21	A single intranasal immunization with inactivated influenza virus and α -galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. <i>Vaccine</i> , 2007, 25, 5189-5198.	3.8	85
22	A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model. <i>Cancer Research</i> , 2007, 67, 7477-7486.	0.9	185
23	Synthesis and Evaluation of 1,2,3-Triazole Containing Analogues of the Immunostimulant α -GalCer. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 585-589.	6.4	169
24	Mediastinal lymph node CD8 α^+ DC initiate antigen presentation following intranasal coadministration of α -GalCer. <i>European Journal of Immunology</i> , 2007, 37, 2127-2137.	2.9	12
25	CD1d-Restricted T Cells License B Cells to Generate Long-Lasting Cytotoxic Antitumor Immunity In vivo. <i>Cancer Research</i> , 2006, 66, 6843-6850.	0.9	64
26	Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens. <i>European Journal of Immunology</i> , 2005, 35, 1381-1390.	2.9	10
27	Optimization of Codon Usage Enhances the Immunogenicity of a DNA Vaccine Encoding Mycobacterial Antigen Ag85B. <i>Infection and Immunity</i> , 2005, 73, 5666-5674.	2.2	63
28	α -Galactosylceramide Can Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral Infection and Tumor. <i>Journal of Immunology</i> , 2005, 175, 3309-3317.	0.8	163
29	Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. <i>International Journal of Cancer</i> , 2004, 111, 86-95.	5.1	47
30	Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. <i>Vaccine</i> , 2003, 21, 3684-3689.	3.8	22